Management of oral anticoagulants in the treatment of venous thromboembolism

European Journal of Internal Medicine

Volumn 12, Issue 2, 2001, Pages 75-85

  Pinede, L ^a   Duhaut, P ^a   Ninet, J ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Deep vein thrombosis; Oral anticoagulant therapy; Oral anticoagulation; Pulmonary embolism; Venous thromboembolism; Vitamin K antagonists

Indexed keywords

ACENOCOUMAROL; ALLOPURINOL; AMIODARONE; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; ANTIVITAMIN K; AZATHIOPRINE; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 7; CARDIOLIPIN ANTIBODY; CISAPRIDE; CLOFIBRATE; COLESTYRAMINE; CYCLOSPORIN; CYTOCHROME P450 2C9; DANAZOL; DEXTROPROPOXYPHENE; ETHINYLESTRADIOL; FIBRINOPEPTIDE; HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENPROCOUMON; PHYTOMENADIONE; SUCRALFATE; SULFINPYRAZONE; THROMBIN; THYROXINE; UNINDEXED DRUG; WARFARIN;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; DRUG INDICATION; DRUG MONITORING; DRUG WITHDRAWAL; HUMAN; LUNG EMBOLISM; PROTHROMBIN TIME; RECURRENCE RISK; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN NECROSIS; TREATMENT OUTCOME; VEIN THROMBOSIS;

EID: 0035073935     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0953-6205(01)00120-0     Document Type: Review

References (101)

1. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals
2. Management of venous thromboembolism: optimization by clinical trials
3. Management of venous thromboembolism
4. Prevention and treatment of venous thromboembolism
5. Antithrombotic therapy for venous thromboembolic disease
6. Treatment of venous thromboembolism
7. Drug trials that have influenced our practice in the treatment of venous thromboembolism
8. Données actuelles sur le traitement de la maladie thrombo-embolique veineuse
9. Evolution of therapies in deep vein thrombosis management
10. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis
11. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis
12. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis
13. Different intensities of oral anticoagulant therapy in the treatment of proximal vein thrombosis
14. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis
15. Low molecular weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial
16. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis
17. Current concepts in anticoagulant therapy
18. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range
19. A comparative study on the quality of oral anticoagulant therapy (warfarin versus acenocoumarol)
20. Warfarin or acenocoumarol: which is better in the management of oral anticoagulants?
21. Variations of prothrombin time, factor VII and protein C with a single daily dose of acenocoumarol
22. Pharmacokinetic and pharmacodynamic variations of acenocoumarol orally administrated either once or twice daily in patients with deep vein thrombosis
23. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis
24. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy
25. Flexible induction dose regimen for warfarin and prediction of maintenance dose
26. On behalf of the European Concerted Action on Anticoagulation. Multicentre randomised study of computerised anticoagulant dosage
27. An overview of the effect of computer-assisted management of anticoagulant therapy on the quality of anticoagulation
28. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism
29. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis
30. Efficacy and safety of early versus late initiation of warfarin during therapy in acute thromboembolism
31. Early versus delayed introduction of oral vitamin K antagonists in combination with low-molecular-weight heparin in the treatment of deep vein thrombosis. A randomized clinical trial
32. Effect of laboratory variation in the prothrombin time ratio on the results of oral anticoagulant therapy
33. Substandard monitoring of warfarin in North America. Time for change
34. Hemorrhagic complications of anticoagulant treatment
35. Anticoagulant related bleeding: clinical epidemiology, prediction, and prevention
36. Evolving models of warfarin management: anticoagulation clinics, patient self-monitoring, and patient self-management
37. Consensus guidelines for coordinated outpatient oral anticoagulation therapy management
38. Comparison of an anticoagulation clinic and usual medical care: anticoagulation control, patient outcomes, and health care costs
39. The management of oral anticoagulant therapy: the patient's point of view
40. Capillary testing in an anticoagulant clinic: comparison of two methods
41. A statistical and clinical evaluation of fingerstick and routine laboratory prothrombin time measurements
42. A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation
43. A 7 year analysis of haemorrhage in patients on long-term anticoagulant treatment
44. Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and hemorrhage
45. Risk factors for complications of chronic anticoagulation. A multicenter study
46. Aging and the anticoagulant response to warfarin therapy
47. Bleeding and thromboembolism during anticoagulant therapy. A population based study in Rochester Minnesota
48. On the behalf of the Italian Study on Complications of Oral Anticoagulant Therapy. Bleeding complications of oral anticoagulant treatment: an inception cohort prospective collaboration study (ISCOAT)
49. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors
50. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The national consortium of anticoagulation clinics
51. Intracranial trauma and non trauma haemorrhage. Complications of warfarin treatment
52. Major bleeding after hospitalization for deep vein thrombosis
53. Interactions of warfarin with drugs and food
54. Determinants of compliance with anticoagulation: a case control study
55. The effect of dietary vitamin K on warfarin induced anticoagulation
56. Retrospective and prospective analyses of the treatment of overanticoagulated patients
57. Prospective evaluation of anticoagulant reversal with oral vitamin K1 while continuing warfarin therapy unchanged
58. Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease
59. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin
60. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
61. Non haemorrhagic adverse reactions of oral anticoagulant therapy
62. Coumarin-induced skin necrosis associated with acquired protein S deficiency and antiphospholipid syndrome
63. For the study of OFRG. Warfarin use and risk for osteoporosis in elderly women
64. Traitement anticoagulant pour maladie thrombo-embolique veineuse: durée optimale de prescription des antivitamines-K. Revue de la littérature
65. Oral anticoagulation in venous thromboembolism: decisions based on more than mere feelings
66. Oral anticoagulation after a first episode of venous thromboembolism: how long?, how strong?
67. The optimal duration of anticoagulant therapy for venous thrombosis
68. Optimal duration of oral anticoagulant therapy following deep vein thrombosis of lower limbs
69. A comparison of 6 weeks with 6 months of oral anticoagulant therapy after a first episode of venous thromboembolism
70. The long term clinical course of acute deep venous thrombosis
71. Recurrent venous thromboembolism after deep vein thrombosis
72. Optimum duration of anticoagulation for deep vein thrombosis and pulmonary embolism
73. Optimal duration of oral anticoagulant therapy: a randomized trial comparing 4 weeks with 3 months of warfarin in patients with proximal deep vein thrombosis
74. A comparison of 3 months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism
75. Duration of anticoagulant therapy in venous thromboembolism
76. One-month versus 6 months therapy with oral anticoagulants after symptomatic deep vein thrombosis
77. The duration of oral anticoagulation after deep vein thrombosis: a randomised study
78. A comparison of 3 and 6 weeks anticoagulation in the treatment of venous thromboembolism
79. Three-months compared with one-year of oral anticoagulant treatment after a first idiopathic deep vein thrombosis: the Warfarin Optimal Duration Italian Trial - WODIT study (abstract no. 2164)
80. Comparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism. A meta-analysis of randomized controlled trials
81. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism
82. Are prothrombin fragment 1+2 and thrombin-antithrombin complexes useful in the management of oral anticoagulant therapy?
83. Prothrombin fragment F1+2 is not predictive for recurrent venous thromboembolism
84. Duration of anticoagulant therapy after first episode of venous thrombosis in patients with inherited thrombophilia
85. Inherited thrombophilia: part 2
86. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden
87. Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis
88. Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: effect of warfarin and prediction by precipitating factors
89. The risk of recurrent deep vein thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation
90. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with G20210A transition in the prothrombin gene
91. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene, DURAC Trial Study Group. Duration of anticoagulation
92. Recurrence of venous thromboembolism in patients with familial thrombophilia
93. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy
94. Oral anticoagulant therapy: efficacy, safety and the low-dose controversy
95. Equal effectiveness of very low intensity anticoagulation and standard low intensity anticoagulation: a pilot study
96. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio
97. Warfarin withdrawal. Pharmacokinetic pharmacodynamic considerations
98. Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants: a prospective study
99. Evolution of blood coagulation and fibrinolysis parameters after abrupt versus gradual withdrawal of acenocoumarol in patients with venous thromboembolism: a double blind randomized study
100. Withdrawn of warfarin after deep vein thrombosis: effects of a low fixed dose on rebound thrombin generation